<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03186339</url>
  </required_header>
  <id_info>
    <org_study_id>IPPM2017TASQ</org_study_id>
    <nct_id>NCT03186339</nct_id>
  </id_info>
  <brief_title>Validation of the &quot;TASQ&quot; in Patients Undergoing SAVR or TF-TAVI</brief_title>
  <acronym>TASQ</acronym>
  <official_title>Validation of the &quot;Toronto Aortic Stenosis Quality of Life Questionnaire&quot; in Patients Undergoing Surgical Aortic Valve Replacement or Transfemoral Transcatheter Aortic Valve Implantation The TASQ Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut f체r Pharmakologie und Pr채ventive Medizin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut f체r Pharmakologie und Pr채ventive Medizin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multi-centre, multi-national registry with a follow-up of 3 months, in five
      European countries and Canada (Toronto), with elective patients undergoing TF-TAVI (n=120)
      and isolated SAVR (n=120), respectively and a control group of 50 patients receiving medical
      treatment only. All patient groups will fill in three different questionnaires to assess
      quality of life in 5 different languages (English, French, German, Italian and Spanish). One
      of these will be a new questionnaire, the Toronto Aortic Stenosis QoL (Quality of Life)
      questionnaire (TASQ).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, there are two cardiovascular disease QoL scales which have been used in studies of
      patients with aortic stenosis - the Minnesota Living with Heart Failure (MLHF) questionnaire
      and the Kansas City Cardiomyopathy Questionnaire (KCCQ).

      The KCCQ has now become the only cited health related (HR) QoL validated scale for use among
      a growing TAVI (Transcatheter Aortic Valve Implantation) patient population; however
      questions on the KCCQ do not reflect the concerns and lifestyle of patients proceeding for
      aortic valve intervention. Many of the questions do not reflect this patient population's
      perspective of well-being in contrast to perceptions by the general cardiac population on
      which it was validated. It is important to capture the disruptions caused by a chronic
      disease and its treatment on lifestyles, activities, and interests; that is interference with
      psychologically meaningful activity. It has been noted that this interference varies by
      disease process and treatment by general scales such as the Illness Intrusiveness Scale .

      Due to issues of limited validity of the KCCQ for TAVI / SAVR (Surgical Aortic Valve
      Replacement) patients related to symptom items not being revised from their original use for
      congestive heart failure, a new original HR-QoL questionnaire was proposed: The &quot;Toronto
      Aortic Stenosis Quality of Life Questionnaire&quot; (TASQ) is a health specific measurement tool
      designed to measure changes in quality of life in aortic stenosis patients. The aim of this
      study is to validate this questionnaire in this specific patient population.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 8, 2017</start_date>
  <completion_date type="Anticipated">September 15, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in QoL as assessed by SF12 (Short Form 12) Questionnaire</measure>
    <time_frame>3 months from baseline examination</time_frame>
    <description>Change in quality of life as assessed by the SF12 using a points system</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in QoL as assessed by KCCQ (The Kansas City Cardiomyopathy Questionnaire)</measure>
    <time_frame>3 months from baseline examination</time_frame>
    <description>Change in quality of life as assessed by the KCCQ using a points system</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in QoL as assessed by TASQ (Toronto Aortic Stenosis Quality of Life Questionnaire)</measure>
    <time_frame>3 months from baseline examination</time_frame>
    <description>Change in quality of life as assessed by the TASQ using a points system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in change in QoL between arms</measure>
    <time_frame>3 months from baseline examination</time_frame>
    <description>Difference in change in QoL between the three intervention arms</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>TAVI patients</arm_group_label>
    <description>patients undergoing TF (transfemoral) TAVI as treatment for the aortic stenosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAVR patients</arm_group_label>
    <description>patients undergoing isolated surgical valve replacement as treatment for the aortic stenosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MM patients</arm_group_label>
    <description>patients in whom the aortic stenosis is medically managed</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TAVI</intervention_name>
    <description>transfemoral transcatheter aortic valve implantation</description>
    <arm_group_label>TAVI patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SAVR</intervention_name>
    <description>isolated surgical valve replacement</description>
    <arm_group_label>SAVR patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MM</intervention_name>
    <description>management of aortic stenosis by medical treatment only</description>
    <arm_group_label>MM patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        120 consecutive patients undergoing TF-TAVI, 120 patients undergoing SAVR, and a control
        group of 50 patients receiving medical treatment will be enrolled. Because of an expected
        loss during follow-up with not all patients returning this will result in about 100
        patients for both TAVI and SAVR and 40 for medical management or 48 per language.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  severe aortic stenosis

          -  age &gt; 18 years

          -  in case of TAVI or SAVR: intention to treat the AS employing an Edwards valve

        Exclusion Criteria:

          -  patients not providing informed consent

          -  patients with major cognitive impairment

          -  emergency patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Rima Styra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto General Hospital, Ontario, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Derk Frank, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UKSH University Clinical Center Schleswig-Holstein, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Simon Kennon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barts Heart Centre, London, UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Bramlage, Prof</last_name>
    <phone>+49(0)3379-3147890</phone>
    <email>peter.bramlage@ippmed.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claudia Lueske, PhD</last_name>
    <phone>+4944718503324</phone>
    <email>claudia.lueske@ippmed.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolaos Bonaros, Prof.</last_name>
      <phone>+4351250480764</phone>
      <email>nikolaos.bonaros@tirol-kliniken.at</email>
    </contact>
    <investigator>
      <last_name>Nikolaos Bonaros, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network, Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>ON 5MG 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rima Styra, MD</last_name>
      <phone>+1 416-340-4825</phone>
      <email>rima.styra@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Rima Styra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Jacques Cartier</name>
      <address>
        <city>Massy</city>
        <zip>91300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauro Romano, MD</last_name>
      <phone>01 69 20 89 16</phone>
      <email>romano.mauro@orange.fr</email>
    </contact>
    <contact_backup>
      <last_name>Thierry Lefevre, MD</last_name>
      <phone>01 69 20 89 16</phone>
      <email>t.lefevre@angio-icps.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mauro Romano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry Lefevre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bichat Hospital - Claude-Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Himbert, MD</last_name>
      <phone>01 40 25 66 01</phone>
      <email>dominique.himbert@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marina Urena-Alcazar, MD</last_name>
      <phone>01 40 25 66 01</phone>
      <email>marina.urena-alcazar@aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Dominique Himbert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marina Urena-Alcazar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UKSH University Clinical Center Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derk Frank, Prof.</last_name>
      <phone>+49 431 500-22812</phone>
      <email>derk.frank@uksh.de</email>
    </contact>
    <investigator>
      <last_name>Derk Frank, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Structual Interventional Cardiology, University Hospital Careggi</name>
      <address>
        <city>Florence</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Di Mario, MD</last_name>
      <email>carlo.dimario@unifi.it</email>
    </contact>
    <contact_backup>
      <last_name>Pierluigi Stefano, MD</last_name>
      <email>stefanop@aou-careggi.toscana.it</email>
    </contact_backup>
    <investigator>
      <last_name>carlo Di Mario, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierluigi Stefano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, University of Verona</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flavio Ribichini, Prof.</last_name>
      <phone>0458122320</phone>
      <email>flavio.ribichini@univr.it</email>
    </contact>
    <investigator>
      <last_name>Flavio Ribichini, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Garcia, MD</last_name>
      <phone>93 274 61 55</phone>
      <email>brunogb51@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Carlos Sureda, MD</last_name>
      <email>carlossureda@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Bruno Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos Sureda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Juan Canalejo Coruna</name>
      <address>
        <city>Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Salgado, MD</last_name>
      <phone>981178000</phone>
      <email>jorge.salgado.fernandez@sergas.es</email>
    </contact>
    <contact_backup>
      <last_name>Cuenca Castillo, MD</last_name>
      <email>josecuenca@cardiocrunia.e.telefonica.net</email>
    </contact_backup>
    <investigator>
      <last_name>Jorge Salgado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cuenca Castillo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barts Heart Centre</name>
      <address>
        <city>London</city>
        <zip>EC1A7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Kennon, MD</last_name>
      <phone>+44 20 3765 8639</phone>
      <email>simon.kennon@bartshealth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Simon Kennon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2017</study_first_submitted>
  <study_first_submitted_qc>June 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>QoL</keyword>
  <keyword>TAVI</keyword>
  <keyword>surgical aortic valve replacement</keyword>
  <keyword>Aortic stenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

